Antineoplastic - HER2 Inhibitors

Antineoplastic HER2 inhibitors are targeted cancer therapies designed to disrupt oncogenic signaling mediated by human epidermal growth factor receptor 2 (HER2/ERBB2) Clinically, these agents play a central role in treating malignancies characterized by HER2 overexpression, gene amplification, or activating mutations, most notably HER2-positive breast cancer, gastric and gastroesophageal junction adenocarcinomas, colorectal cancer, and select non-small cell lung cancers

Antineoplastic HER2 inhibitors are targeted cancer therapies designed to disrupt oncogenic signaling mediated by human epidermal growth factor receptor 2 (HER2/ERBB2) This drug class encompasses monoclonal antibodies, small-molecule tyrosine kinase inhibitors, and antibody-drug conjugates that selectively bind the extracellular domain or inhibit the intracellular kinase activity of HER2, thereby blocking downstream proliferative pathways and promoting tumor cell death Clinically, these agents pl...

This drug class encompasses monoclonal antibodies, small-molecule tyrosine kinase inhibitors, and antibody-drug conjugates that selectively bind the extracellular domain or inhibit the intracellular kinase activity of HER2, thereby blocking downstream proliferative pathways and promoting tumor cell death

This drug class encompasses monoclonal antibodies, small-molecule tyrosine kinase inhibitors, and antibody-drug conjugates that selectively bind the extracellular domain or inhibit the intracellular kinase activity of HER2, thereby blocking downstream proliferative pathways and promoting tumor cell death

Clinically, these agents play a central role in treating malignancies characterized by HER2 overexpression, gene amplification, or activating mutations, most notably HER2-positive breast cancer, gastric and gastroesophageal junction adenocarcinomas, colorectal cancer, and select non-small cell lung cancers